心肌损伤生物标志物的检测在心脏疾病临床诊断上被广泛应用,但是在新药的非临床安全评价方面,心肌损伤标志物的应用相对滞后。
The biomarkers of myocardial injury are used widely in clinical diagnosis of heart diseases. However, application of the biomarker in drug preclinical safety evaluation is relatively less.
心肌损伤生物标志物的检测在心脏疾病临床诊断上被广泛应用,但是在新药的非临床安全评价方面,心肌损伤标志物的应用相对滞后。
The biomarkers of myocardial injury are used widely in clinical diagnosis of heart diseases. However, application of the biomarker in drug preclinical safety evaluation is relatively less.
应用推荐